Department of Radiology, Neuroradiology, and minimal-invasive Therapy, Munich Klinik Bogenhausen Englschalkingerstr. 77 81925, Munich, Germany.
Br J Radiol. 2020 Sep 1;93(1113):20200112. doi: 10.1259/bjr.20200112. Epub 2020 Aug 14.
Interventional oncology (IO) has proven to be highly efficient in the local therapy of numerous malignant tumors in addition to surgery, chemotherapy, and radiotherapy. Due to the advent of immune-oncology with the possibility of tumor control at the molecular and cellular levels, a system change is currently emerging. This will significantly rule oncology in the coming decades. Therefore, one cannot think about IO in the 21st century without considering immunology. For IO, this means paying much more attention to the immunomodulatory effects of the interventional techniques, which have so far been neglected, and to explore the synergistic possibilities with immuno-oncology. It can be expected that the combined use of IO and immuno-oncology will help to overcome the limitations of the latter, such as limited local effects and a high rate of side-effects. To do this, however, sectoral boundaries must be removed and interdisciplinary research efforts must be strengthened. In case of success, IO will face an exciting future.
介入肿瘤学 (IO) 除了手术、化疗和放疗之外，已被证明在许多恶性肿瘤的局部治疗中非常有效。随着免疫肿瘤学的出现，有可能在分子和细胞水平上控制肿瘤，目前正在出现系统的变化。这将在未来几十年显著主导肿瘤学。因此，如果不考虑免疫学，就无法想象 21 世纪的 IO。对于 IO 来说，这意味着要更加关注介入技术的免疫调节作用，而这些作用迄今为止一直被忽视，并探索与免疫肿瘤学的协同可能性。可以预期，IO 和免疫肿瘤学的联合使用将有助于克服后者的局限性，例如局部效果有限和副作用发生率高。然而，要做到这一点，必须消除部门界限，加强跨学科的研究努力。如果成功，IO 将面临一个令人兴奋的未来。
